Navigation Links
Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
Date:6/19/2013

New York, New York (PRWEB) June 19, 2013

As Januvia lawsuit claims involving pancreatitis and pancreatic cancer continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) recently held a meeting to discuss the safety of Januvia and other diabetes drugs known as incretin mimetics. According to a June 12th report from Bloomberg.com, the FDA may seek additional data from the makers of Januvia and similar drugs, following a recent study that indicated the medications could increase risks for pancreatic cancer. One of the options being considered by the agency is a large clinical trial designed to show patterns of adverse events. *

“In light of the possible link between Januvia and pancreatic cancer, we certainly hope that the FDA will order more studies of these drugs,” says Bernstein Liebhard LLP, nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Januvia lawsuit evaluations to patients who took the medication and were diagnosed with pancreatic cancer or pancreatitis.

Januvia Lawsuits
Incretin mimetics like Januvia help regulate blood sugar by stimulating insulin production by the pancreas. In 2009, information was added to the drug’s label regarding a potential risk for Januvia pancreatitis, after the FDA became aware of 88 post-marketing cases of acute pancreatitis that occurred in patients taking the drug.** In 2011, a study published in the journal Gastroenterology found that use of Januvia appeared to increase the risk of pancreatitis by as much as six-fold. The same study found a possible link between Januvia and pancreatic cancer.***

The FDA’s recent meeting was prompted by data from an unpublished study that drugs like Januvia could cause precancerous changes in the cell of the pancreas, Bloomberg.com said. Just prior to the meeting, the American Diabetes Association called for an independent review of all incretin mimetics to provide clarity to patients and health care providers in light of the recent controversy.****

Court documents indicate that Januvia lawsuits filed on behalf of patients who used the drug and developed pancreatic cancer and pancreatitis are already mounting in courts throughout the country. On July 25, 2013, the U.S. Judicial Panel on Multidistrict Litigation (JPML) will meet to discuss whether or not a multidistrict litigation should be established for all federally-filed claims involving incretin mimetics. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

Alleged victims of Januvia pancreatitis or pancreatic cancer may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more about filing a Januvia lawsuit, please visit Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*bloomberg.com/news/2013-06-12/merck-joins-novo-to-reassure-safetynof-diabetes-drugs.html
**fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm; September 25, 2009
***gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
****diabetes.org/for-media/2013/american-diabetes-association-incretin-therapy.html

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.januvialawsuit2013.com/

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb10850018.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Announces Addition of Januvia Cancer Resource Center
2. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
3. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
4. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
5. Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
6. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
7. LawyersandSettlements.com Issues Report on Prostate Health Claim Lawsuits and Propecia Side Effect Litigation
8. The Law Office of Wolf & Pravato, The Alters Firm and Morelli Ratner File Class Action Lawsuit Against Global Spray Foam Manufacturer
9. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
10. New Lawsuit Alleges Teen Molestation by Ex-Deputy
11. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... TX (PRWEB) , ... July 27, 2017 , ... ... receive a new set of teeth in a single office visit from Dr. ... and comfortable treatment solutions to his East Texas patients, including Teeth-in-a-Day® dental ...
(Date:7/27/2017)... ... July 27, 2017 , ... Somnoware, a leading ... (PSG) distributed scoring solution to its healthcare management platform. This solution provides physicians ... speed and functionality of scoring in the cloud is on par with doing ...
(Date:7/27/2017)... California (PRWEB) , ... July 27, 2017 , ... The Los Angeles leg of the ... 3rd, 2017 at 7:00pm and will be held at the Clive Davis Theater inside the ... the Camo Jacket, chronicles the story of the iconic Welsh rock musician, Mike Peters (of ...
(Date:7/27/2017)... ... 2017 , ... Team Novo Nordisk, the world’s first all-diabetes professional cycling team, ... a stagiaire for the remainder of the 2017 season. One of our best development ... Tour of Utah. , “Every season we are excited to move an athlete from ...
(Date:7/26/2017)... ... July 26, 2017 , ... Capillus, LLC has announced the redesign ... The new Flexible Fitting Design offers a more comfortable, adaptable fit and is available ... the improvements to the home-use laser therapy caps intended to improve both user experience ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... LAUDERDALE, Fla. , July 25, 2017  Debbie,s Dream Foundation: Curing Stomach ... Luncheon on Monday, September 25, 2017 at the Bonaventure Resort & Spa in ... ... Gendler, DDF Founder and President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... ...
(Date:7/21/2017)... , July 21, 2017  Endo International plc (NASDAQ: ... a comprehensive review of its manufacturing network, the Company ... distribution facilities in Huntsville, Alabama . ... place over the next 12 to 18 months. The ... by declining volumes of commoditized products and these restructuring ...
(Date:7/15/2017)... 2017 Enterin Inc., a Philadelphia ... (PD), today announced the completion of a $12.7 million Series ... III, as well as the participation of existing investors. ... have the support of New Ventures III and our current ... of the potential of our platform technology to transform the ...
Breaking Medicine Technology: